Human Albumin Csl Behring (Human Plasma Protein)

Human Albumin Csl Behring is indicated for clinical situations where plasma volume or albumin levels need rapid restoration.

• Treatment of hypovolemia due to blood loss, dehydration, or trauma.
• Management of hypoalbuminemia associated with liver disease, nephrotic syndrome, or malnutrition.
• Volume support in patients with extensive burns to counter fluid loss.
• Adjunct therapy for circulatory shock when plasma oncotic pressure is compromised.
• Intra‑operative fluid management for major surgeries with anticipated large fluid shifts.
• Support for patients with renal replacement therapy who develop low oncotic pressure.

• Human Albumin Csl Behring works by supplying exogenous albumin, the principal protein responsible for maintaining plasma oncotic pressure. The infused albumin molecules bind water within the vascular compartment, thereby drawing fluid from the interstitial space into the bloodstream. This increase in oncotic pressure expands intravascular volume, improves circulatory stability, and enhances tissue perfusion. The effect is rapid because albumin distributes uniformly throughout the plasma pool.

Adverse reactions to Human Albumin Csl Behring are generally related to the infusion process and the protein nature of the product.

Common

• Transient fever or chills occurring during or shortly after infusion.
• Mild changes in blood pressure, including temporary hypotension or hypertension.
• Headache that resolves without specific treatment.
• Nausea or vomiting that is generally brief.
• Localized urticaria, erythema, or itching at the infusion site.

Serious

• Anaphylactic or severe allergic reaction, potentially with respiratory distress and skin rash.
• Acute hemolysis manifested by sudden drop in hemoglobin and hemoglobinuria.
• Volume overload leading to pulmonary edema, especially in patients with cardiac dysfunction.
• Thromboembolic events such as deep‑vein thrombosis or pulmonary embolism.
• Theoretical risk of transmission of infectious agents despite viral inactivation steps.

When using Human Albumin Csl Behring, clinicians should evaluate patient history and monitor for conditions that may increase risk of complications.

• Assess fluid status and avoid use in patients with uncontrolled congestive heart failure or severe renal impairment.
• Verify absence of known hypersensitivity to albumin or any plasma‑derived products.
• Use caution in individuals with active infection, as albumin may affect immune response.
• Monitor vital signs and central venous pressure during and after infusion.
• Adjust dose in patients with severe hypoalbuminemia to prevent rapid shifts in oncotic pressure.
• Consider the risk of volume overload in elderly or frail patients.
• Document lot number and expiration date for traceability.

Human Albumin Csl Behring may interact with other intravenous therapies or medications that influence fluid balance and coagulation.

Avoid

• Concomitant administration with other volume expanders (e.g., synthetic colloids) that may cause excessive intravascular volume.
• Simultaneous infusion of high‑dose diuretics without careful monitoring, risking hypovolemia.
• Use with agents that increase capillary permeability, such as high‑dose steroids, which can diminish albumin efficacy.

Use with caution

• Concurrent use of anticoagulants or antiplatelet drugs; monitor for bleeding due to dilutional effects.
• Administration with vasopressors; observe hemodynamic response closely.
• Infusion alongside blood products; ensure compatible timing to avoid volume overload.